IDL Diagnostics AB (OSTO:IDLDX) Net Margin %: 7.24% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:IDLDX IDL Diagnostics AB OSTO:IDLDX
55 GF Score
Price kr0.42
GF Value kr0.54
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is IDL Diagnostics AB Net Margin %?

IDL Diagnostics AB OSTO:IDLDX +3.69% 55 Net Margin % is 7.24% as of Mar. 2026. GuruFocus rates OSTO:IDLDX with a GF Score™ of 55/100 and a GF Value™ of kr0.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks worse than 70.94% on this metric.

Net margin is calculated as Net Income divided by its Revenue. IDL Diagnostics AB's Net Income for the three months ended in Mar. 2026 was kr1.21 Mil. IDL Diagnostics AB's Revenue for the three months ended in Mar. 2026 was kr16.74 Mil. Therefore, IDL Diagnostics AB's net margin for the quarter that ended in Mar. 2026 was 7.24%.

The historical rank and industry rank for IDL Diagnostics AB's Net Margin % or its related term are showing as below:

OSTO:IDLDX' s Net Margin % Range Over the Past 10 Years
Min: -28633.33   Med: -1535.68   Max: -5.81
Current: -33.41

OSTO:IDLDX's Net Margin % is ranked worse than
70.94% of 203 companies
in the Medical Diagnostics & Research industry
Industry Median: -2.81 vs OSTO:IDLDX: -33.41

IDL Diagnostics AB  (OSTO:IDLDX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

IDL Diagnostics AB Net Margin % Related Terms

IDL Diagnostics AB Net Margin % Historical Data

* Premium members only.

The historical data trend for IDL Diagnostics AB's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDL Diagnostics AB Net Margin % Chart

IDL Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -417.01 -159.45 -137.78 -5.81 -22.88

IDL Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.48 -146.79 -27.10 -8.99 7.24

OSTO:IDLDX vs TMO, DHR, IDXX: Net Margin % Comparison

For the Diagnostics & Research subindustry, IDL Diagnostics AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IDL Diagnostics AB Net Margin % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Net Margin % distribution charts can be found below:

* The bar in red indicates where IDL Diagnostics AB's Net Margin % falls into.


OSTO:IDLDX
55GF Score
IDL Diagnostics AB OSTO:IDLDX
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDL Diagnostics AB Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

IDL Diagnostics AB's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-12.151/53.108
=-22.88 %

IDL Diagnostics AB's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=1.211/16.737
=7.24 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 7.24% mean?
IDL Diagnostics AB (OSTO:IDLDX) has a Net Margin % of 7.24% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on IDL Diagnostics AB and its competitors. According to the industry distribution chart, IDL Diagnostics AB ranks #144 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 70.9%.
Is IDL Diagnostics AB's Net Margin % too high?
IDL Diagnostics AB's current Net Margin % is 7.24%. Based on the distribution chart, IDL Diagnostics AB ranks #144 out of 203 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #144 out of 203 companies for Net Margin %. This places IDL Diagnostics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on IDL Diagnostics AB and its competitors. IDL Diagnostics AB's current Net Margin % is 7.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.42 — trading 21.9% below its estimated fair value. The current Net Margin % is 7.24%. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current Net Margin % is 7.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?

Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued. The current stock price of kr0.42 is trading 21.9% below its estimated GF Value™ of kr0.54. GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.

Key valuation signals for OSTO:IDLDX:

  • Net Margin %: 7.24%
  • GF Value™: kr0.54 vs. price of kr0.42 (21.9% below fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IDL Diagnostics AB Business Description

Address Karlsbodavagen 39, Bromma, Stockholm, SWE, 168 67
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score

Get the complete analysis for OSTO:IDLDX

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.42
Price
kr0.54
GF Value